KCM
ARCT icon

KRS Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

KRS Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,400
Closed -$51K – 134
2021
Q4 		$51K Buy
+1,400
New +$57K 0.04% 228

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KRS Capital Management's ARCT Position: Q1 2022 in Review

KRS Capital Management sold out of Arcturus Therapeutics (ARCT) in Q1 2022, closing a stake of 1,400 shares — an estimated $51K sold.

KRS Capital Management first reported a position in ARCT in Q4 2021 and held it in 1 quarter. The position peaked at $51K in Q4 2021. 130 funds tracked by Wall St. Rank hold ARCT as of Q1 2022.

  • KRS Capital Management reported no remaining Arcturus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • KRS Capital Management sold 1,400 Arcturus Therapeutics shares in Q1 2022, an estimated $51K.
  • KRS Capital Management first reported a position in Arcturus Therapeutics in Q4 2021 and held it in 1 quarter.
  • KRS Capital Management's Arcturus Therapeutics position peaked at $51K in Q4 2021.
  • 130 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.